FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912436760> ?p ?o ?g. }

• W2912436760 endingPage "728" @default.
• W2912436760 startingPage "721" @default.
• W2912436760 abstract "The use of biologic therapy has increased over the past decade well beyond primary autoimmune diseases. Indeed, a recent trial using an anti-IL-1beta antibody reduced second myocardial infarction (MI) in those who have had MI. Psoriasis is a chronic inflammatory disease often treated with biologics when severe, is associated with increased risk of MI, in part driven by high-risk coronary plaque phenotypes by coronary computed tomography angiography (CCTA). We hypothesized that we would observe a reduction in inflammatory-driven phenotypes of coronary plaque, including non-calcified coronary plaque burden and lipid-rich necrotic core in those treated with biologic therapy after one-year compared with non-biologic therapy. In a prospective, observational study, 290 participants were recruited from 1 January 2013 through 31 October 2018 with 215 completing one-year follow-up. Of the 238, 121 consecutive participants who were biologic treatment naïve at baseline were included. A blinded reader (blinded to patient demographics, visit and treatment) quantified total coronary plaque burden and plaque subcomponents (calcified and non-calcified) in the three main coronary vessels >2 mm using dedicated software (QAngio, Medis, Netherlands). Psoriasis patients were middle-aged [mean (standard deviation) age, 50.5 (12.1) years], mostly male (n = 70, 58%) with low cardiovascular risk by Framingham score [median (interquartile range, IQR), 3 (1–6)] and had moderate to severe skin disease at baseline [median (IQR) Psoriasis Area Severity Index, PASI, 8.6 (5.3–14.0)]. Biologic therapy was associated with a 6% reduction in non-calcified plaque burden (P = 0.005) reduction in necrotic core (P = 0.03), with no effect on fibrous burden (P = 0.71). Decrease in non-calcified plaque burden in the biologic treated group was significant compared with slow plaque progression in non-biologic treated (Δ, −0.07 mm2 vs. 0.06 mm2; P = 0.02) and associated with biologic treatment beyond adjustment for traditional cardiovascular risk factors (β = 0.20, P = 0.02). In this observational study, we demonstrate that biologic therapy in severe psoriasis was associated with favourable modulation of coronary plaque indices by CCTA. These findings highlight the importance of systemic inflammation in coronary artery disease and support the conduct of larger, randomized trials." @default.
• W2912436760 created "2019-02-21" @default.
• W2912436760 creator A5003760958 @default.
• W2912436760 creator A5007894377 @default.
• W2912436760 creator A5020348286 @default.
• W2912436760 creator A5025791584 @default.
• W2912436760 creator A5029448532 @default.
• W2912436760 creator A5033787787 @default.
• W2912436760 creator A5033795032 @default.
• W2912436760 creator A5037356234 @default.
• W2912436760 creator A5044504500 @default.
• W2912436760 creator A5053807316 @default.
• W2912436760 creator A5066516536 @default.
• W2912436760 creator A5075827012 @default.
• W2912436760 creator A5075911442 @default.
• W2912436760 creator A5077687421 @default.
• W2912436760 creator A5080726626 @default.
• W2912436760 creator A5086010156 @default.
• W2912436760 creator A5086804964 @default.
• W2912436760 creator A5087435433 @default.
• W2912436760 date "2019-02-05" @default.
• W2912436760 modified "2023-10-16" @default.
• W2912436760 title "Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study" @default.
• W2912436760 cites W1865705147 @default.
• W2912436760 cites W1943930704 @default.
• W2912436760 cites W1947718272 @default.
• W2912436760 cites W1964828756 @default.
• W2912436760 cites W1967937911 @default.
• W2912436760 cites W2007448220 @default.
• W2912436760 cites W2026082319 @default.
• W2912436760 cites W2027415701 @default.
• W2912436760 cites W2028621745 @default.
• W2912436760 cites W2044465471 @default.
• W2912436760 cites W2059796825 @default.
• W2912436760 cites W2065523538 @default.
• W2912436760 cites W2066227212 @default.
• W2912436760 cites W2100963925 @default.
• W2912436760 cites W2116098803 @default.
• W2912436760 cites W2117758842 @default.
• W2912436760 cites W2128722360 @default.
• W2912436760 cites W2137418944 @default.
• W2912436760 cites W2139585854 @default.
• W2912436760 cites W2152705713 @default.
• W2912436760 cites W2156919621 @default.
• W2912436760 cites W2508251329 @default.
• W2912436760 cites W2594308496 @default.
• W2912436760 cites W2613380263 @default.
• W2912436760 cites W2617191705 @default.
• W2912436760 cites W2748400555 @default.
• W2912436760 cites W2749050364 @default.
• W2912436760 cites W2783677300 @default.
• W2912436760 cites W2804753859 @default.
• W2912436760 cites W2898446684 @default.
• W2912436760 cites W2900284252 @default.
• W2912436760 cites W988932408 @default.
• W2912436760 doi "https://doi.org/10.1093/cvr/cvz009" @default.
• W2912436760 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6432047" @default.
• W2912436760 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30721933" @default.
• W2912436760 hasPublicationYear "2019" @default.
• W2912436760 type Work @default.
• W2912436760 sameAs 2912436760 @default.
• W2912436760 citedByCount "157" @default.
• W2912436760 countsByYear W29124367602019 @default.
• W2912436760 countsByYear W29124367602020 @default.
• W2912436760 countsByYear W29124367602021 @default.
• W2912436760 countsByYear W29124367602022 @default.
• W2912436760 countsByYear W29124367602023 @default.
• W2912436760 crossrefType "journal-article" @default.
• W2912436760 hasAuthorship W2912436760A5003760958 @default.
• W2912436760 hasAuthorship W2912436760A5007894377 @default.
• W2912436760 hasAuthorship W2912436760A5020348286 @default.
• W2912436760 hasAuthorship W2912436760A5025791584 @default.
• W2912436760 hasAuthorship W2912436760A5029448532 @default.
• W2912436760 hasAuthorship W2912436760A5033787787 @default.
• W2912436760 hasAuthorship W2912436760A5033795032 @default.
• W2912436760 hasAuthorship W2912436760A5037356234 @default.
• W2912436760 hasAuthorship W2912436760A5044504500 @default.
• W2912436760 hasAuthorship W2912436760A5053807316 @default.
• W2912436760 hasAuthorship W2912436760A5066516536 @default.
• W2912436760 hasAuthorship W2912436760A5075827012 @default.
• W2912436760 hasAuthorship W2912436760A5075911442 @default.
• W2912436760 hasAuthorship W2912436760A5077687421 @default.
• W2912436760 hasAuthorship W2912436760A5080726626 @default.
• W2912436760 hasAuthorship W2912436760A5086010156 @default.
• W2912436760 hasAuthorship W2912436760A5086804964 @default.
• W2912436760 hasAuthorship W2912436760A5087435433 @default.
• W2912436760 hasBestOaLocation W29124367601 @default.
• W2912436760 hasConcept C11783203 @default.
• W2912436760 hasConcept C119060515 @default.
• W2912436760 hasConcept C126322002 @default.
• W2912436760 hasConcept C16005928 @default.
• W2912436760 hasConcept C164705383 @default.
• W2912436760 hasConcept C188816634 @default.
• W2912436760 hasConcept C23131810 @default.
• W2912436760 hasConcept C2778213512 @default.
• W2912436760 hasConcept C2779134260 @default.
• W2912436760 hasConcept C2780564577 @default.
• W2912436760 hasConcept C500558357 @default.

• next